An interventional study of LLM-based chatbot and Telephone counseling in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Alcohol-Related Liver Disease, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include:
3,255 studies on the registry are indexed under Fibrosis; 465 are open to participants now.
This study's planned enrollment of 50 is close to the median of 50 across 2,130 interventional studies indexed under Fibrosis.
Browse Fibrosis studies →The University of Hong Kong is the lead sponsor of 1,262 studies on the registry; 340 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
1. Hong Kong residents aged 18 years or above 2. Diagnosed of MASLD:
Presence of metabolic dysfunction, indicated by at least one of the following:
Overweight or obesity (body mass index [BMI] ≥25 kg/m²),
Type 2 diabetes mellitus, ③Dyslipidemia (elevated triglycerides [≥150 mg/dL] or low high-density lipoprotein [HDL] cholesterol [\<40 mg/dL for men, \<50 mg/dL for women]), ④Hypertension (blood pressure ≥130/85 mmHg or use of antihypertensive medication).
Exclusion Criteria:
LLM-based chatbot + Alcohol Brief Intervention
Behavioral: LLM-based chatbot · Behavioral: Alcohol Brief Intervention
Telephone counseling + Alcohol Brief Intervention
Behavioral: Telephone counseling · Behavioral: Alcohol Brief Intervention
Over the three months following randomisation, an LLM-based chatbot will interact with each participant individually to deliver four personalized sessions of alcohol reduction information and advice, and participants will also be allowed to contact the chatbot at any time.
Over the three months following randomisation, a trained counsellor will conduct four individual daytime telephone sessions with each participant to provide personalised information and advice on reducing alcohol consumption.
Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet
Recruitment rate
Number of participants divided by the number of eligible subjects
Time frame: Through recruitment completion, about 12 months
Retention rate
Number of participants completed the follow-up divided by the number of participants
Time frame: 6 months after randomisation
Weekly alcohol consumption
Assessed by questions 1 and 2 of AUDIT-C
Time frame: 3 months after randomisation
Eligibility rate
Number of eligible patients divided by the number of patients screened
Time frame: Through recruitment completion, about 12 months
Weekly alcohol consumption
Assessed by questions 1 and 2 of AUDIT-C
Time frame: 6 months after randomisation
Frequency of binge drinking in the past 30 days
Self-reported
Time frame: 3 months after randomisation
Frequency of binge drinking in the past 30 days
Self-reported
Time frame: 6 months after randomisation
Frequency of heavy drinking in the past 30 days
Self-reported
Time frame: 3 months after randomisation
Frequency of heavy drinking in the past 30 days
Self-reported
Time frame: 6 months after randomisation
AUDIT score and level
Assessed by the Alcohol Use Disorders Identification Test
Time frame: 3 months after randomisation
AUDIT score and level
Assessed by the Alcohol Use Disorders Identification Test
Time frame: 6 months after randomisation
Planned drinking in the coming 30 days
Self-reported
Time frame: 3 months after randomisation
Planned drinking in the coming 30 days
Self-reported
Time frame: 6 months after randomisation
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Hong Kong